These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9687212)

  • 21. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA targets unapproved drugs.
    Young D
    Am J Health Syst Pharm; 2007 Feb; 64(4):347-8. PubMed ID: 17299170
    [No Abstract]   [Full Text] [Related]  

  • 23. The FDA drug approval process: focus on pediatric labeling.
    Brummel GL
    Neonatal Netw; 2001 Apr; 20(3):49-51. PubMed ID: 12144214
    [No Abstract]   [Full Text] [Related]  

  • 24. Delegations of authority and organization; issuance of written notices--FDA. Final rule.
    Fed Regist; 1992 May; 57(85):18823-4. PubMed ID: 10118461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug development process for a product with a primary pediatric indication.
    Allen AJ; Michelson D
    J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory issues in pediatric psychopharmacology.
    Laughren TP
    J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1276-82. PubMed ID: 8885581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA perspectives on supplement use by patients on antithrombotic therapy.
    Kim MJ
    Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297
    [No Abstract]   [Full Text] [Related]  

  • 28. FDA eases medication guide distribution requirements.
    Traynor K
    Am J Health Syst Pharm; 2011 Apr; 68(8):649-50. PubMed ID: 21460167
    [No Abstract]   [Full Text] [Related]  

  • 29. The new FDA pregnancy labeling requirements for drugs.
    Frederiksen MC
    J Midwifery Womens Health; 2011; 56(3):303-7. PubMed ID: 21535377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics.
    Novak E; Allen PJ
    Pediatr Nurs; 2007; 33(1):64-70. PubMed ID: 17411005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lost in transmission--FDA drug information that never reaches clinicians.
    Schwartz LM; Woloshin S
    N Engl J Med; 2009 Oct; 361(18):1717-20. PubMed ID: 19846841
    [No Abstract]   [Full Text] [Related]  

  • 32. Is pediatric labeling really necessary?
    Christensen ML; Helms RA; Chesney RW
    Pediatrics; 1999 Sep; 104(3 Pt 2):593-7. PubMed ID: 10469796
    [No Abstract]   [Full Text] [Related]  

  • 33. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 34. FDA approves once-daily efavirenz formulation, revised labeling.
    AIDS Treat News; 2002 Mar; (378):7. PubMed ID: 11965921
    [No Abstract]   [Full Text] [Related]  

  • 35. Proposed NSAID package insert labeling.
    Food and Drug Administration U.S. Public Health Service
    J Pain Palliat Care Pharmacother; 2006; 20(1):49-55. PubMed ID: 16687359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
    Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview.
    Woo JJ
    Thromb Res; 2005; 117(1-2):193-6; discussion 201-7. PubMed ID: 16253311
    [No Abstract]   [Full Text] [Related]  

  • 38. Dermatology community applauds new FDA sunscreen regulations: labeling requirements aim to make it easier for consumers to select a sunscreen.
    Printz C
    Cancer; 2012 Jan; 118(1):1-3. PubMed ID: 22222879
    [No Abstract]   [Full Text] [Related]  

  • 39. Requirements for FDA-approved patient information spelled out in final rule.
    Am J Health Syst Pharm; 1999 Jan; 56(2):107-8. PubMed ID: 10030523
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA prohibits extralabel use of two drug classes.
    J Am Vet Med Assoc; 1997 Aug; 211(3):269. PubMed ID: 9262656
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.